Table 2. Correlation between plasma PD-L1 levels and patients’ characteristics.
| Patients characteristic | PD-L1 classes (based on medianvalue) - N (%) | p value | |
|---|---|---|---|
| negative | positive | ||
| Age | 0.58 | ||
| ≤70.4 | 13 (46.4) | 15 (53.6) | |
| >70.4 | 11 (39.3) | 17 (60.7) | |
| Gender | 0.86 | ||
| Male | 16 (42.1) | 22 (57.9) | |
| Female | 8 (44.4) | 10 (55.6) | |
| Smoking history | 0.71 | ||
| Never/Former | 19 (44.2) | 24 (55.8) | |
| Current | 5 (38.5) | 8 (61.5) | |
| Number of metastaticsites | 0.06 | ||
| 1 | 2 (50.0) | 2 (50.0) | |
| 2 | 8 (50.0) | 8 (50.0) | |
| 3 | 11 (47.8) | 12 (52.2) | |
| 4 | 2 (25.0) | 6 (75.0) | |
| 5 | 1 (33.3) | 2 (66.7) | |
| 6 | 0 (0.0) | 2 (100.0) | |
| EGFR status | 0.97 | ||
| Mutateda | 5 (45.5) | 6 (54.5) | |
| Wild type | 17 (45.9) | 20 (54.1) | |
| KRAS status | 0.42 | ||
| Mutatedb | 5 (38.5) | 8 (61.5) | |
| Wild type | 13 (52.0) | 12 (48.0) | |
| ALK status | 0.79 | ||
| Rearranged | 1 (50.0) | 1 (50.0) | |
| Wild type | 15 (40.5) | 22 (59.5) | |
| ROS1 status | 0.36 | ||
| Rearranged | 1 (100.0) | 0 (0.0) | |
| Wild type | 6 (33.3) | 12 (66.7) | |
aEGFR mutations included: exon 18 = 1 (9.0%); exon 19 = 4 (36.4%); exon 20 = 2 (18.2%); exon 21 = 4 (36.4%); bKRAS mutations included: codon 12 = 13 (100%).